Add BrightSurf on Google Email

Science News for January 26, 2018


Potential enzyme as therapeutic target for diabetes

A team of Japanese researchers has identified Sirt2 as a key player in regulating hepatic glucose uptake, which is impaired in obesity and type 2 diabetes. The study found that Sirt2 regulates the dissociation of glucokinase from its regulatory protein, GKRP, through post-translational modifications.

SourceKanazawa University·JournalNature Communications·DateJan 26, 2018

What are memories made of?

Researchers have discovered that three distinct varieties of the protein AKT play different roles in brain health, with AKT2 targeting brain cancer and AKT1 promoting memory formation. The study's findings hold promise for developing targeted therapies for conditions like Alzheimer's disease and schizophrenia.

UNIST researchers develop highly stretchable aqueous batteries

Researchers at UNIST have developed a highly stretchable rechargeable lithium-ion battery based on aqueous electrolytes, using a simple and cost-effective solution process. The breakthrough involves a bioinspired Jabuticaba-like hybrid carbon/polymer composite that retains its electrical conductivity under high strain rates.

SourceUlsan National Institute of Science and Technology(UNIST)·JournalAdvanced Energy Materials·DateJan 26, 2018

Health visitors use of video helps vulnerable families

A new study from Aarhus University found that health visitors using video feedback with the Marte Meo method can improve early mother-child relationships in vulnerable families. The research involved 69 families who received extra visits with video clips, showing a significant improvement compared to a control group.

SourceAarhus University·JournalBMC Pregnancy and Childbirth·DateJan 26, 2018

Drug trial protocol redactions by industry sponsors exposed

Researchers found widespread redactions in commercially sponsored trial protocols, making them useless for assessing ethical justification and identifying discrepancies with publications. The study highlights the mistrust in industry-sponsored drug trials and calls for unconditional access to trial protocols and data.

SourceSAGE·JournalJournal of the Royal Society of Medicine·DateJan 26, 2018